SOLO-Symbicort® in the treatment of persistent asthma in adolescents & adults

Study identifier:D5890L00004

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A comparison of Symbicort® Single inhaler Therapy (Symbicort® 200 Turbuhaler® 1 inhalation b.i.d. plus as needed) & conventional best practice for the treatment of persistent asthma in adolescents & adults–a 26-week, randomised, open-label, parallel group, multicentre study

Medical condition

asthma

Phase

Phase 3

Healthy volunteers

Study drug

Budesonide/formoterol Turbuhaler

Sex

All

Actual Enrollment

1300

Study type

Interventional

Age

12 Years - Minutes

Date

Study Start Date: 01 May 2004

Primary Completion Date: 01 Oct 2005

Study Completion Date: 01 Oct 2005

Study design

Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals

Collaborators

Inclusion and exclusion criteria

No locations available

Arms	Assigned Interventions

Documents available

http://www.astrazeneca.com/node/emailtriage.aspx
Download
https://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&studyid=521&filename=CSR-D5890L00004.pdf
Download
CSR-D5890L00004.pdf
Download
Trial Results Summaries
Available here

Contacts

Contact

AstraZeneca Canada Information Center

1-800-668-6000

Investigators

Principal Investigator

AstraZeneca Rita Medical Science Director

AstraZeneca